• Publications
  • Influence
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.
Glioblastoma (GBM) is a brain tumor that carries a dismal prognosis and displays considerable heterogeneity. We have recently identified recurrent H3F3A mutations affecting two critical amino acidsExpand
  • 1,114
  • 89
  • Open Access
The whole-genome landscape of medulloblastoma subtypes
Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose debilitating effects on the developing child, and highlight the need for molecularly targeted treatments withExpand
  • 290
  • 14
  • Open Access
Epigenomic alterations define lethal CIMP-positive ependymomas of infancy
Ependymomas are common childhood brain tumours that occur throughout the nervous system, but are most common in the paediatric hindbrain. Current standard therapy comprises surgery and radiation, butExpand
  • 387
  • 13
The MOF chromobarrel domain controls genome-wide H4K16 acetylation and spreading of the MSL complex.
The histone H4 lysine 16 (H4K16)-specific acetyltransferase MOF is part of two distinct complexes involved in X chromosome dosage compensation and autosomal transcription regulation. Here we showExpand
  • 56
  • 7
Drosophila Dosage Compensation Involves Enhanced Pol II Recruitment to Male X-Linked Promoters
Promoting the Male X Chromosome In mammals and fruit flies, females have a double dose of the X chromosome compared to males, and to compensate for this imbalance, in fruit flies, transcription fromExpand
  • 71
  • 5
Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis.
PURPOSE Posterior fossa ependymoma comprises two distinct molecular variants termed EPN_PFA and EPN_PFB that have a distinct biology and natural history. The therapeutic value of cytoreductiveExpand
  • 80
  • 4
  • Open Access
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma
Telomerase reverse transcriptase (TERT) promoter mutations were recently shown to drive telomerase activity in various cancer types, including medulloblastoma. However, the clinical and biologicalExpand
  • 114
  • 4
  • Open Access
Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays
It is now clear that medulloblastoma (MB), one of the most clinically challenging paediatric brain tumours, is not a single disease entity. Rather, it comprises four distinct molecular subgroups (WntExpand
  • 176
  • 3
Heterogeneity within the PF-EPN-B ependymoma subgroup
Posterior fossa ependymoma comprise three distinct molecular variants, termed PF-EPN-A (PFA), PF-EPN-B (PFB), and PF-EPN-SE (subependymoma). Clinically, they are very disparate and PFB tumors areExpand
  • 20
  • 3
Medulloblastoma subgroups remain stable across primary and metastatic compartments
Medulloblastoma comprises four distinct molecular variants with distinct genetics, transcriptomes, and outcomes. Subgroup affiliation has been previously shown to remain stable at the time ofExpand
  • 57
  • 1